Anna Osmukhina

Ranolazine in patients with incomplete revascularisation after percutaneous coronary intervention (RIVER-PCI): a multicentre, randomised, double-blind, placebo-controlled trial

Giora Weisz, Philippe Généreux, Andrés Íñiguez et al. · The Lancet · 2015 · 116 citations

Medicine, Cardiology, Pharmacology +15

Effects of Ranolazine on Angina and Quality of Life After Percutaneous Coronary Intervention With Incomplete Revascularization

Karen P. Alexander, Giora Weisz, Kristi Prather et al. · Circulation · 2015 · 64 citations

Medicine, Cardiology, Pharmacotherapy +13

A Phase 1 Dose-Escalation Study of the Cardiac Myosin Inhibitor Aficamten in Healthy Participants

Fady I. Malik, Laura Robertson, Danielle Armas et al. · JACC Basic to Translational Science · 2022 · 64 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +15

Phase II study to assess the efficacy, safety and tolerability of the mitotic spindle kinesin inhibitor AZD4877 in patients with recurrent advanced urothelial cancer

Robert J. Jones, Jacqueline Vuky, Tony Elliott et al. · Investigational New Drugs · 2013 · 59 citations

Medicine, Oncology, Pharmacology +12

Phase I/II multicenter study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of AZD4877 in patients with refractory acute myeloid leukemia

Hagop M. Kantarjian, Wendy Stock, Martin S. Tallman et al. · Investigational New Drugs · 2011 · 51 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +9